<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37488532</PMID><DateCompleted><Year>2023</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2369</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>24</Day></PubDate></JournalIssue><Title>BMC nephrology</Title><ISOAbbreviation>BMC Nephrol</ISOAbbreviation></Journal><ArticleTitle>Rare case of exostosin 1/exostosin 2-related membranous lupus nephritis concomitant with dual ANCA- and anti-GBM antibody-associated crescentic glomerulonephritis effectively diagnosed by mass spectrometry: a case report.</ArticleTitle><Pagination><StartPage>218</StartPage><MedlinePgn>218</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">218</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12882-023-03268-1</ELocationID><Abstract><AbstractText Label="BACKGROUND">Recent developments in mass spectrometry (MS) have revealed target antigens for membranous nephropathy (MN), including phospholipase A2 receptor and exostosin 1/exostosin 2 (EXT1/2). EXT1/2 are known antigens of autoimmune disease-related MN, especially membranous lupus nephritis. We describe the case of an elderly man who developed nephrotic syndrome followed by progressive renal dysfunction.</AbstractText><AbstractText Label="CASE PRESENTATION">A 78-year-old man presented with rapidly progressive renal dysfunction with proteinuria and hematuria. Three years previously, he had developed leg edema but did not receive any treatment. Laboratory tests showed elevated anti-nuclear antibody (Ab), anti-dsDNA Ab titer, and hypocomplementemia, indicating systemic lupus erythematous. Myeloperoxidase anti-neutrophil cytoplasmic Ab (ANCA) and anti-glomerular basement membrane (GBM) Ab were also detected. The renal pathologic findings were compatible with crescentic glomerulonephritis (GN), whereas non-crescentic glomeruli exhibited MN without remarkable endocapillary or mesangial proliferative change. Immunofluorescence microscopy revealed glomerular IgG, C3, and C1q deposition. All IgG subclasses were positive in glomeruli. Anti-PLA2R Ab in serum was negative. MS analysis was performed to detect the antigens of MN, and EXT1/2 was detected in glomeruli. Therefore, we reached a diagnosis of membranous lupus nephritis concurrent with both ANCA-associated vasculitis and anti-GBM-GN. The simultaneous occurrence of these three diseases is extremely rare.</AbstractText><AbstractText Label="CONCLUSIONS">This is the first report of EXT1/2-related membranous lupus nephritis concurrent with ANCA-associated vasculitis and anti-GBM-GN. This case demonstrates the usefulness of MS in diagnosing complicated cases of MN.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Yamazaki</LastName><ForeName>Takuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-Ku, SagamiharaKanagawa, 252-0374, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Takahashi</LastName><ForeName>Haruka</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-Ku, SagamiharaKanagawa, 252-0374, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Omigawahimawari Clinic, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takeuchi</LastName><ForeName>Kazuhiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-Ku, SagamiharaKanagawa, 252-0374, Japan. takekazu04044@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Analytic Human Pathology, Nippon Medical School, Tokyo, Japan. takekazu04044@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakamoto</LastName><ForeName>Emi</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Analytic Human Pathology, Nippon Medical School, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tominaga</LastName><ForeName>Kenta</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Analytic Human Pathology, Nippon Medical School, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakurabayashi</LastName><ForeName>Syun</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-Ku, SagamiharaKanagawa, 252-0374, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abe</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-Ku, SagamiharaKanagawa, 252-0374, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sano</LastName><ForeName>Takashi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Aihara Hospital, Kanagawa, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wada</LastName><ForeName>Yukihiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-Ku, SagamiharaKanagawa, 252-0374, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuwahara</LastName><ForeName>Naomi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Analytic Human Pathology, Nippon Medical School, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimizu</LastName><ForeName>Akira</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Analytic Human Pathology, Nippon Medical School, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takeuchi</LastName><ForeName>Yasuo</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-Ku, SagamiharaKanagawa, 252-0374, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Nephrol</MedlineTA><NlmUniqueID>100967793</NlmUniqueID><ISSNLinking>1471-2369</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019268">Antibodies, Antineutrophil Cytoplasmic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C051951">antiglomerular basement membrane antibody</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.4.1.-</RegistryNumber><NameOfSubstance UI="D017351">N-Acetylglucosaminyltransferases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.4.1.224</RegistryNumber><NameOfSubstance UI="C105200">exostosin-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.4.1.224</RegistryNumber><NameOfSubstance UI="C101411">exostosin-2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056648" MajorTopicYN="Y">Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019268" MajorTopicYN="N">Antibodies, Antineutrophil Cytoplasmic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005921" MajorTopicYN="Y">Glomerulonephritis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015432" MajorTopicYN="Y">Glomerulonephritis, Membranoproliferative</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015433" MajorTopicYN="Y">Glomerulonephritis, Membranous</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013058" MajorTopicYN="N">Mass Spectrometry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017351" MajorTopicYN="N">N-Acetylglucosaminyltransferases</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ANCA-associated vasculitis</Keyword><Keyword MajorTopicYN="N">Anti-GBM glomerulonephritis</Keyword><Keyword MajorTopicYN="N">Exostosin &#xbd;</Keyword><Keyword MajorTopicYN="N">Lupus nephritis</Keyword><Keyword MajorTopicYN="N">Mass spectrometry</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>28</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>25</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>24</Day><Hour>23</Hour><Minute>41</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37488532</ArticleId><ArticleId IdType="pmc">PMC10364369</ArticleId><ArticleId IdType="doi">10.1186/s12882-023-03268-1</ArticleId><ArticleId IdType="pii">10.1186/s12882-023-03268-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pu SJ, Luo SF, Wu YJ, Cheng HS, Ho HH. The clinical features and prognosis of lupus with disease onset at age 65 and older. Lupus. 2000;9(2):96&#x2013;100. doi: 10.1191/096120300678828109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120300678828109</ArticleId><ArticleId IdType="pubmed">10787005</ArticleId></ArticleIdList></Reference><Reference><Citation>Terao C, Yamada R, Mimori T, Yamamoto K, Sumida T. A nationwide study of SLE in Japanese identified subgroups of patients with clear signs patterns and associations between signs and age or sex. Lupus. 2014;23(13):1435&#x2013;1442. doi: 10.1177/0961203314547790.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203314547790</ArticleId><ArticleId IdType="pubmed">25122185</ArticleId></ArticleIdList></Reference><Reference><Citation>Jarrot PA, Chiche L, Hervier B, Daniel L, Vuiblet V, Bardin N, Bertin D, Terrier B, Amoura Z, Andr&#xe9;s E, et al. Systemic Lupus Erythematosus and Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Overlap Syndrome in Patients With Biopsy-Proven Glomerulonephritis. Medicine (Baltimore) 2016;95(22):e3748. doi: 10.1097/MD.0000000000003748.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000003748</ArticleId><ArticleId IdType="pmc">PMC4900711</ArticleId><ArticleId IdType="pubmed">27258503</ArticleId></ArticleIdList></Reference><Reference><Citation>Hounoki H, Shinoda K, Matsui A, Okumura M, Yamaguchi S, Kakeshita K, Yamazaki H, Koike T, Makino T, Tobe K. A Case of Systemic Lupus Erythematosus and Antineutrophil Cytoplasmic Antibodies-Associated Vasculitis Overlap Syndrome. Case Rep Rheumatol. 2021;2021:6690658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7808812</ArticleId><ArticleId IdType="pubmed">33505756</ArticleId></ArticleIdList></Reference><Reference><Citation>Hervier B, Hamidou M, Haroche J, Durant C, Mathian A, Amoura Z. Systemic lupus erythematosus associated with ANCA-associated vasculitis: an overlapping syndrome? Rheumatol Int. 2012;32(10):3285&#x2013;3290. doi: 10.1007/s00296-011-2055-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-011-2055-z</ArticleId><ArticleId IdType="pubmed">21805174</ArticleId></ArticleIdList></Reference><Reference><Citation>Li C, Zhou ML, Liang DD, Wang JJ, Yang J, Zeng CH, Liu ZH, Zhang HT. Treatment and clinicopathological characteristics of lupus nephritis with anti-neutrophil cytoplasmic antibody positivity: a case-control study. BMJ Open. 2017;7(7):e015668. doi: 10.1136/bmjopen-2016-015668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2016-015668</ArticleId><ArticleId IdType="pmc">PMC5642651</ArticleId><ArticleId IdType="pubmed">28756384</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner-Stokes T, Wilson HR, Morreale M, Nunes A, Cairns T, Cook HT, Pusey CD, Tarzi RM, Lightstone L. Positive antineutrophil cytoplasmic antibody serology in patients with lupus nephritis is associated with distinct histopathologic features on renal biopsy. Kidney Int. 2017;92(5):1223&#x2013;1231. doi: 10.1016/j.kint.2017.04.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2017.04.029</ArticleId><ArticleId IdType="pmc">PMC5652376</ArticleId><ArticleId IdType="pubmed">28750930</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogo AB, Lusco MA, Najafian B, Alpers CE. AJKD Atlas of Renal Pathology: Anti-Glomerular Basement Membrane Antibody-Mediated Glomerulonephritis. Am J Kidney Dis. 2016;68(5):e29&#x2013;e30. doi: 10.1053/j.ajkd.2016.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2016.09.003</ArticleId><ArticleId IdType="pubmed">27772636</ArticleId></ArticleIdList></Reference><Reference><Citation>Hellmark T, Niles JL, Collins AB, McCluskey RT, Brunmark C. Comparison of anti-GBM antibodies in sera with or without ANCA. J Am Soc Nephrol. 1997;8(3):376&#x2013;385. doi: 10.1681/ASN.V83376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.V83376</ArticleId><ArticleId IdType="pubmed">9071706</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayne DR, Marshall PD, Jones SJ, Lockwood CM. Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. Kidney Int. 1990;37(3):965&#x2013;970. doi: 10.1038/ki.1990.72.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.1990.72</ArticleId><ArticleId IdType="pubmed">2179617</ArticleId></ArticleIdList></Reference><Reference><Citation>Sethi S. New 'Antigens' in Membranous Nephropathy. J Am Soc Nephrol. 2021;32(2):268&#x2013;278. doi: 10.1681/ASN.2020071082.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2020071082</ArticleId><ArticleId IdType="pmc">PMC8054892</ArticleId><ArticleId IdType="pubmed">33380523</ArticleId></ArticleIdList></Reference><Reference><Citation>Wada Y, Iyoda M, Suzuki T, Tachibana S, Kanazawa N, Matsumoto K, Honda H. Immunopathological analysis of the expression of glomerular exostosin 1 and exostosin 2 in Japanese patients with lupus nephritis. Virchows Arch. 2021;479(5):997&#x2013;1005. doi: 10.1007/s00428-021-03164-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00428-021-03164-9</ArticleId><ArticleId IdType="pubmed">34302213</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos-Casals M, Garc&#xed;a-Carrasco M, Brito MP, L&#xf3;pez-Soto A, Font J. Autoimmunity and geriatrics: clinical significance of autoimmune manifestations in the elderly. Lupus. 2003;12(5):341&#x2013;355. doi: 10.1191/0961203303lu383ed.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203303lu383ed</ArticleId><ArticleId IdType="pubmed">12765297</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71(9):1400&#x2013;1412. doi: 10.1002/art.40930.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40930</ArticleId><ArticleId IdType="pmc">PMC6827566</ArticleId><ArticleId IdType="pubmed">31385462</ArticleId></ArticleIdList></Reference><Reference><Citation>Sethi S, Madden BJ, Debiec H, Charlesworth MC, Gross L, Ravindran A, Hummel AM, Specks U, Fervenza FC, Ronco P. Exostosin 1/Exostosin 2-Associated Membranous Nephropathy. J Am Soc Nephrol. 2019;30(6):1123&#x2013;1136. doi: 10.1681/ASN.2018080852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2018080852</ArticleId><ArticleId IdType="pmc">PMC6551791</ArticleId><ArticleId IdType="pubmed">31061139</ArticleId></ArticleIdList></Reference><Reference><Citation>Lwmm Rops A, Loeven MA, van Gemst JJ, Eversen I, Van Wijk XM, Dijkman HB, van Kuppevelt TH, Berden JHM, Rabelink TJ, Esko JD, et al. Modulation of heparan sulfate in the glomerular endothelial glycocalyx decreases leukocyte influx during experimental glomerulonephritis. Kidney Int. 2014;86(5):932&#x2013;942. doi: 10.1038/ki.2014.115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2014.115</ArticleId><ArticleId IdType="pubmed">24759151</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravindran A, Casal Moura M, Fervenza FC, Nasr SH, Alexander MP, Fidler ME, Herrera Hernandez LP, Zhang P, Grande JP, Cornell LD, et al. In Patients with Membranous Lupus Nephritis, Exostosin-Positivity and Exostosin-Negativity Represent Two Different Phenotypes. J Am Soc Nephrol. 2021;32(3):695&#x2013;706. doi: 10.1681/ASN.2020081181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1681/ASN.2020081181</ArticleId><ArticleId IdType="pmc">PMC7920177</ArticleId><ArticleId IdType="pubmed">33478971</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Lan P, Yu X, Liu X, Sun J, Xie L, Lu W, Xie X. Analysis of the Expression of Exostosins and Clinicopathological Features in Membranous Lupus Nephritis in a Chinese Cohort. Kidney Int Rep. 2022;7(10):2295&#x2013;2298. doi: 10.1016/j.ekir.2022.07.164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ekir.2022.07.164</ArticleId><ArticleId IdType="pmc">PMC9546740</ArticleId><ArticleId IdType="pubmed">36217518</ArticleId></ArticleIdList></Reference><Reference><Citation>Tominaga K, Uchida T, Imakiire T, Itoh K, Shimazaki H, Nakanishi K, Kumagai H, Oshima N. Anti-neutrophil cytoplasmic antibody-associated glomerulonephritis with detection of myeloperoxidase and phospholipase A(2) receptor in membranous nephropathy-lesions: report of two patients with microscopic polyangiitis. BMC Nephrol. 2018;19(1):120. doi: 10.1186/s12882-018-0922-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12882-018-0922-5</ArticleId><ArticleId IdType="pmc">PMC5966893</ArticleId><ArticleId IdType="pubmed">29792176</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S, Li C, Huang J, Zhou Y, Gao C, Sun M, Wang R, Chen B. Clinical and pathological features of anti-glomerular basement membrane disease associated with membranous nephropathy: an observational study. Ren Fail. 2022;44(1):1904&#x2013;1914. doi: 10.1080/0886022X.2022.2141645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/0886022X.2022.2141645</ArticleId><ArticleId IdType="pmc">PMC9662048</ArticleId><ArticleId IdType="pubmed">36351876</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogo AB, Lusco MA, Najafian B, Alpers CE. AJKD Atlas of Renal Pathology: Pauci-immune Necrotizing Crescentic Glomerulonephritis. Am J Kidney Dis. 2016;68(5):e31&#x2013;e32. doi: 10.1053/j.ajkd.2016.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2016.09.002</ArticleId><ArticleId IdType="pubmed">27772637</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Yan Y, Cui Z, Yang R, Zhao MH. The immunoglobulin G subclass distribution of anti-GBM autoantibodies against rHalpha3(IV)NC1 is associated with disease severity. Hum Immunol. 2009;70(6):425&#x2013;429. doi: 10.1016/j.humimm.2009.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2009.04.004</ArticleId><ArticleId IdType="pubmed">19364515</ArticleId></ArticleIdList></Reference><Reference><Citation>Serratrice J, Chiche L, Dussol B, Granel B, Daniel L, Jego-Desplat S, Disdier P, Swiader L, Berland Y, Weiller PJ. Sequential development of perinuclear ANCA-associated vasculitis and anti-glomerular basement membrane glomerulonephritis. Am J Kidney Dis. 2004;43(3):e26&#x2013;30. doi: 10.1053/j.ajkd.2003.11.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2003.11.019</ArticleId><ArticleId IdType="pubmed">14981638</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy JB, Hammad T, Coulthart A, Dougan T, Pusey CD. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int. 2004;66(4):1535&#x2013;1540. doi: 10.1111/j.1523-1755.2004.00917.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1523-1755.2004.00917.x</ArticleId><ArticleId IdType="pubmed">15458448</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutgers A, Slot M, van Paassen P, van Breda VP, Heeringa P, Tervaert JW. Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase-ANCAs in crescentic glomerulonephritis. Am J Kidney Dis. 2005;46(2):253&#x2013;262. doi: 10.1053/j.ajkd.2005.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2005.05.003</ArticleId><ArticleId IdType="pubmed">16112043</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>